Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Usama Gergis, Aaron Martin, Alex Vogel, Jeff Smith, Andreas Klein, Ran Reshef, Rajneesh Nath, Adam J. Olszewski, Alan List, Alex F. Herrera, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2024-210499

Published: 2024

Journal Articles

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

David A. Sallman, Alan List

Blood (2019) 133 (10): 1039–1048.

https://doi.org/10.1182/blood-2018-10-844654

Published: 2019

Journal Articles

Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium

Rami S Komrokji, MD, Xiao-Feng Wang, phD, Najla H Al Ali, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Gail J. Roboz, MD, Steven D Gore, Sean Hobson, Cassandra Zimmerman, Eric Padron, MD, Jaroslaw P. Maciejewski, MD, PhD, Alan List, MD, Mikkael A. Sekeres, MD, MS

Blood (2013) 122 (21): 1505.

https://doi.org/10.1182/blood.V122.21.1505.1505

Published: 2013

Journal Articles

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Rami S Komrokji, MD, Najla H Al Ali, Eric Padron, MD, Ji-Hyun Lee, PhD, Nancy Hillgruber, RN, Sara Tinsley, ARNP, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 1506.

https://doi.org/10.1182/blood.V122.21.1506.1506

Published: 2013

Journal Articles

Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior To Azanucleosides

Rami S Komrokji, MD, Maria G. Corrales-Yepez, MD, Najla H Al Ali, Eric Padron, MD, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 1507.

https://doi.org/10.1182/blood.V122.21.1507.1507

Published: 2013

Journal Articles

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

Viet Q. Ho, PharmD, BCOP, Robert Cade, PharmD, Gene A. Wetzstein, PharmD, BCOP, Van D Hoang, PharmD, BCOP, Alan List, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 3951.

https://doi.org/10.1182/blood.V122.21.3951.3951

Published: 2013

Journal Articles

JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML

Sateesh Kunigal, PhD, Jamie Teer, PhD, Jeff Painter, BS, Sean J Yoder, MS, Euhnee Kim, PhD, Ling Zhang, MD, Jeffrey E Lancet, MD, Rami S. Komrokji, MD, Omar Abdel-Wahab, MD, Alan List, MD, Pearlie K Epling-Burnette, PhD, Eric Padron, MD

Blood (2013) 122 (21): 2772.

https://doi.org/10.1182/blood.V122.21.2772.2772

Published: 2013

Journal Articles

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Maria Gabriela Corrales-Yepez, MD, Teresa Field, MD, PhD, Alan List, MD, Claudio Anasetti, MD, Janelle Perkins, PharmD, Najla H Al Ali, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Mohamed A. Kharfan-Dabaja, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 5222.

https://doi.org/10.1182/blood.V122.21.5222.5222

Published: 2013

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA)

Rami S Komrokji, MD, Vu H. Duong, M.D., Ling Zhang, MD, Ji-Hyun Lee, PhD, Eric Padron, MD, Jeffrey E Lancet, MD, Alan List, MD

Blood (2013) 122 (21): 2760.

https://doi.org/10.1182/blood.V122.21.2760.2760

Published: 2013

Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD

Blood (2013) 122 (21): 1315.

https://doi.org/10.1182/blood.V122.21.1315.1315

Published: 2013

Journal Articles

Whole Exome Sequencing (“mutatome”) Of Deletion 5q

Naoko Hosono, MD, PhD, Hideki Makishima, MD, PhD, Bartlomiej P Przychodzen, PhD, Andres Jerez, MD, Chantana Polprasert, MD, Yuichi Shiraishi, PhD, Kenichi Chiba, PhD, Hiroko Tanaka, BA, Satoru Miyano, PhD, Kenichi Yoshida, MD, Masashi Sanada, MD, PhD, Jacqueline Boultwood, PhD, Alan List, MD, Mikkael A. Sekeres, MD, MS, Seishi Ogawa, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2013) 122 (21): 656.

https://doi.org/10.1182/blood.V122.21.656.656

Published: 2013

Journal Articles

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Rami S Komrokji, MD, Austin G Kulasekararaj, MBBS, MD, MRCP, FRCP, Najla H Al Ali, Shahram Y Kordasti, MD, PhD, Emily Bart-smith, Craig Benjamin, Eric Padron, MD, Ling Zhang, MD, Jeffrey E Lancet, MD, Alan List, MD, Ghulam J Mufti, FRCP, FRCPath, M.D., Pearlie K Epling-Burnette, PhD

Blood (2013) 122 (21): 746.

https://doi.org/10.1182/blood.V122.21.746.746

Published: 2013

Journal Articles

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Pearlie K Epling-Burnette, PhD, Ying Han, MD, Adam W Mailloux, PhD, Ling Zhang, MD, Jessica M. McDaniel, PhD, Rajadhyaksha Anjali, PhD, Sheng Wei, MD, Ritchie David, PhD, Paul Neeson, PhD, Rami S. Komrokji, MD, Alan List, MD

Blood (2013) 122 (21): 748.

https://doi.org/10.1182/blood.V122.21.748.748

Published: 2013

Journal Articles

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Mikkael A. Sekeres, MD, MS, Arlene S. Swern, PhD, Aristoteles Giagounidis, MD, PhD, Alan List, MD, Brigitte Schlegelberger, MD, PhD, Pierre Fenaux, MD, PhD, Jack Shiansong Li, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 390.

https://doi.org/10.1182/blood.V122.21.390.390

Published: 2013

Journal Articles

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Lianchun Xiao, Al Ali Najla, Asmita Mishra, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Jeffery Bryan, Hillary Prescott, David P. Steensma, MD, Mikkael A. Sekeres, MD, MS, Gail J. Roboz, MD, Alan List, MD, Hagop M Kantarjian, MD, Rami S Komrokji, MD

Blood (2013) 122 (21): 388.

https://doi.org/10.1182/blood.V122.21.388.388

Published: 2013

Journal Articles

Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients

Marie Sebert, Rami S Komrokji, MD, Mikkael A. Sekeres, MD, MS, Thomas Prebet, MD PhD, Thomas Cluzeau, MD, PhD, Valeria Santini, MD, Alessandro Sanna, Najla H Al Ali, Sean Hobson, Virginie Eclache, MD, Alan List, MD, Pierre Fenaux, MD, PhD, Lionel Ades

Blood (2013) 122 (21): 389.

https://doi.org/10.1182/blood.V122.21.389.389

Published: 2013

Journal Articles

Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes

Ganesan Keerthivasan, MBBS, MD, Baobing Zhao, PhD, Chad E Harris, Ling Zhang, MD, Juehua Gao, M.D., Ph.D., James McElherne, Jing Yang, Ashley A Basiorka, Matthew Schipma, Jacqueline Boultwood, Amit Verma, Alan List, MD, David A. Williams, MD, Peng Ji, MD, PhD

Blood (2013) 122 (21): 1557.

https://doi.org/10.1182/blood.V122.21.1557.1557

Published: 2013

Journal Articles

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Prerna Rastogi, MBBS, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Eric Padron, MD, Elizabeth M. Sagatys, MD, Mojdeh Naghashpour, MD, PhD, Jiangchuan Tao, MD, PhD, John M. Bennett, Alan List, MD, Jeffrey E Lancet, MD, Kenneth S. Zuckerman, MD, Ling Zhang, MD

Blood (2013) 122 (21): 4076.

https://doi.org/10.1182/blood.V122.21.4076.4076

Published: 2013

Journal Articles

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Aristoteles Giagounidis, MD, PhD, Alan List, MD, Eva Hellström-Lindberg, MD, PhD, Mikkael A. Sekeres, MD, MS, Ghulam J. Mufti, MD, PhD, Brigitte Schlegelberger, MD, PhD, John Morrill, Chengqing Wu, Barry S. Skikne, MD, Pierre Fenaux, MD, PhD, Gudrun Göhring, MD

Blood (2013) 122 (21): 1538.

https://doi.org/10.1182/blood.V122.21.1538.1538

Published: 2013

NARROW

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes

Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium

A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients

Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior To Azanucleosides

A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin

JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML

Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA)

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Whole Exome Sequencing (“mutatome”) Of Deletion 5q

Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases

Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure

Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients

Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only